ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

NCI Role, Issues In Education Considered By DRCCA Board

August 21, 1981

Proposed Regulations for Center Grants In Federal Register

October 29, 1976

FDA, HCFA Form Council On Biomedical Imaging.

November 10, 2000

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009